Close Menu

NEW YORK (GenomeWeb) – Cepheid has launched a CE marked bladder cancer test that is currently commercially available in Germany and will launch throughout Europe in the coming months.

The Xpert Bladder Cancer Monitor test runs on the firm's GeneXpert molecular diagnostics system. It has about a 94 percent negative predictive value, so could be particularly useful in more confidently ruling out bladder cancer and reducing the need for more invasive testing, Cepheid said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Feb
23
Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

Feb
24
Sponsored by
SCHOTT MINIFAB

Developing a fully integrated consumable cartridge for an automated diagnostic platform is a significant challenge. More challenging still is developing such a cartridge in response to a deadly global virus pandemic amid market uncertainty and extraordinary time constraints.